Clinical trial
A Randomized Phase II Trial to Assess the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency (HRD Patients With Deleterious BRCA1/2 Tumor or Germline Mutation and/or HRD Score High)
NCT02789332 is registered in ClinicalTrials.gov with GBG Forschungs GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase II Trial to Assess the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency (HRD Patients With Deleterious BRCA1/2 Tumor or Germline Mutation and/or HRD Score High)
- Lead sponsor
- GBG Forschungs GmbH
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2016
- Completion date
- February 29, 2020
- Enrollment
- 107 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.
brca 1 /2 and / or hrd, breast cancer, hrpos breast neoplasms, triple negative breast neoplasms